| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_297c3871221a400859f27be454c1c542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd7b2245f810fa80a4285fca04b3bdd9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2302
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12M25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0068 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M1-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate |
2020-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b39093a66de7f6fd3169e6646d1d27fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a36f91d61546746f59a7a1a5b4a90863 |
| publicationDate |
2021-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102236011-B1 |
| titleOfInvention |
Mass proliferation culture method of NK cell |
| abstract |
The present invention relates to a method for culturing NK cells, and more particularly, 1) separating a pellet of immune cells of a peripheral blood mononuclear cell (PBMC) from blood; 2) culturing the PBMC in RPMI culture medium in an incubator coated with anti-CD16 antibody; 3) subculturing the PBMC; And 4) activating NK cells by treating the PBMC with a cytokine selected from the cytokine group consisting of IL-2, IL-15 and IL-2+IL-15. will be. The present invention is an optimal combination capable of effectively activating cells when treated with NK cells using IL-2 and IL-15 among various cytokines. Culture is possible, and when using this, apoptosis or killing ability of cancer cells can be promoted, and thus can be used as an effective immune cell therapeutic agent for preventing or treating cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022102887-A1 |
| priorityDate |
2020-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |